ArticleJournal of gastroenterology and hepatology2022

Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.

Y J Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.